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7Comparison Between Magnetic Resonance Imaging and
Computed Tomography of the Lung in Patients With Cystic
Fibrosis With Regard to Clinical, Laboratory, and Pulmonary
Functional Parameters
Diane M. Renz, MD,* Oriane Scholz, MD,* Joachim Böttcher, MD,† Martin H. Maurer, MD,*
Timm Denecke, MD,* Carsten Schwarz, MD,‡ Alexander Pfeil, MD,§ Florian Streitparth, MD,*
Alexander Huppertz, MD,* Anne Mehl, MD,‡ Alexander Poellinger, MD,* Doris Staab, MD,‡
Bernd Hamm, MD,* and Hans-Joachim Mentzel, MDk
Objective: To evaluate whether magnetic resonance imaging (MRI) is effective
as computed tomography (CT) in determining morphologic and functional pul-
monary changes in patients with cystic fibrosis (CF) in association with multiple
clinical parameters.
Materials and Methods: Institutional review board approval and patient written
informed consent were obtained. In this prospective study, 30 patients with CF
(17 men and 13 women; mean (SD) age, 30.2 (9.2) years; range, 19–52 years) were
included. Chest CTwas acquired by unenhanced low-dose technique for clinical
purposes. Lung MRI (1.5 T) comprised T2- and T1-weighted sequences before
and after the application of 0.1-mmol·kg−1 gadobutrol, also considering lung
perfusion imaging. All CT and MR images were visually evaluated by using 2 dif-
ferent scoring systems: the modified Helbich and the Eichinger scores. Signal
intensity of the peribronchial walls and detected mucus on T2-weighted images
as well as signal enhancement of the peribronchial walls on contrast-enhanced
T1-weighted sequences were additionally assessed on MRI. For the clinical evalu-
ation, the pulmonary exacerbation rate, laboratory, and pulmonary functional
parameters were determined.
Results: The overall modified Helbich CT score had a mean (SD) of 15.3 (4.8)
(range, 3–21) and median of 16.0 (interquartile range [IQR], 6.3). The overall modi-
fiedHelbichMRscore showed slightly, not significantly, lower values (Wilcoxon rank
sum test and Student t test; P > 0.05): mean (SD) of 14.3 (4.7) (range, 3–20) and me-
dian of 15.0 (IQR, 7.3). Without assessment of perfusion, the overall Eichinger score
resulted in the following values for CT vs MR examinations: mean (SD), 20.3 (7.2)
(range, 4–31); and median, 21.0 (IQR, 9.5) vs mean (SD), 19.5 (7.1) (range, 4–33);
and median, 20.0 (IQR, 9.0). All differences between CTandMR examinations were
not significant (Wilcoxon rank sum tests and Student t tests; P > 0.05). In general, the
correlations of the CT scores (overall and different imaging parameters) to the clinical
parameters were slightly higher compared to the MRI scores. However, if all addi-
tional MRI parameters were integrated into the scoring systems, the correlations
reached the values of the CT scores. The overall image quality was significantly
higher for the CTexaminations compared to the MRI sequences.Received for publication February 28, 2015; and accepted for publication, after revision,
April 24, 2015.
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Copyright © 2015 Wolters Kluwer HConclusions: One major diagnostic benefit of lung MRI in CF is the possible
acquisition of several different morphologic and functional imaging features
without the use of any radiation exposure. Lung MRI shows reliable associations
with CT and clinical parameters, which suggests its implementation in CF for
routine diagnosis, which would be particularly important in follow-up imaging
over the long term.
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C ystic fibrosis (CF) is the most prevalent autosomal recessive dis-ease in the white population.1,2 This inherited progressive disease
is caused by mutations of the CF transmembrane conductance regulator
gene localized on the long arm of chromosome 7.1 Various possible
mutations of this gene result in an impaired transepithelial chloride se-
cretion in sweat, salivary, and intestinal glands as well as in the air-
ways.1,2 Pulmonary manifestations are responsible for more than 90%
of the morbidity and mortality in patients with CF.2–4 Owing to ad-
vances in management and treatment of these pulmonary manifesta-
tions, the life expectancy of patients is continuously increasing, with a
current median survival of approximately 40 years.3–5
Accurate diagnosis and monitoring of CF-related lung disease is
crucial in providing early and effective treatment and also in improving
the overall prognosis. Thin-sliced chest computed tomography (CT) is
the current criterion standard to visualize best the characteristic mor-
phologic pulmonary changes due to its high spatial resolution.6–8
Thereby, scoring systems offer a quantitative and more reproducible as-
sessment compared to sole visual imaging analysis.8–10 As repeated,
life-long pulmonary imaging is required, the cumulative radiation expo-
sure can itself become a complication for patients with CF, particularly
with regard to their increasing life expectancy, even if low-dose CT pro-
tocols are used; in the case of 1 to 2 CTexaminations per year, cumula-
tive radiation doses of more than 40 mSv can be achieved.8–11
Magnetic resonance imaging (MRI) of the lung has increasingly
been proposed as a radiation-free diagnostic alternative in patients with
CF.12–14 In 1987, Fiel et al15 first described the use of lung MRI in
young adults with CF. However, the early investigations on lung MRI
could not provide comparable findings to CT examinations.15,16 With
the development and ongoing improvement ofMRI sequences and equip-
ment, such as multichannel radiofrequency coils, the temporal and spatial
resolution of lungMRI has been continuously optimized.17–20 Puderbach
et al12 found high agreement of morphologic pulmonary changes be-
tween MRI and CT in CF. Although spatial resolution of MRI is still in-
ferior compared to CT, MRI has the advantage of assessing morphologic
and functional aspects of lung parenchyma without any ionizing radia-
tion; furthermore,MRI can provide distinct tissue characterization based
on signal intensities in T1- and T2-weighted imaging as well as en-
hancement features after contrast medium application.12,21–24www.investigativeradiology.com 733
ealth, Inc. All rights reserved.
Renz et al Investigative Radiology • Volume 50, Number 10, October 2015The principle aim of this investigation was to determine the diag-
nostic value of MRI to visualize pulmonary manifestations in patients
with CF compared to unenhanced low-dose CT and, moreover, to clin-
ical findings. The main difference between this prospective study and
published investigations is the cross-sectional correlation of all imaging
results to laboratory and pulmonary functional parameters as well as to
possible pulmonary exacerbation. Furthermore, the overall image qual-
ity of the CTandMR examinations was assessed. All CT series andMRI
sequences were evaluated using 2 different scoring systems to find the
best possible evaluation score for CT and MR images.
MATERIALS AND METHODS
Study Standards and Design
This prospective investigationwas performed in accordancewith
the Declaration of Helsinki and was approved by the local ethics com-
mittee; all patients gave written consent before study participation after
being thoroughly informed. Patients with verified CF were included if
they were at least 18 years of age, were referred to clinic, and received
unenhanced low-dose CTat the Department of Radiology (Charité Uni-
versity Medicine, Berlin, Germany) for clinical indications, such as
acute pulmonary exacerbation. Besides CT, all patients agreed to undergo
an MR examination with the use of gadobutrol (Gd-DO3A-butriol;
Gadovist, Bayer HealthCare Pharmaceuticals, Berlin, Germany), a mac-
rocyclic contrast agent with low risk of developing nephrogenic
systemic fibrosis.25–27
Exclusion criteria were the following:
- Contraindications to MRI, eg, pacemaker, claustrophobia, severe
obesity;
- Application of any contrast mediumwithin 24 hours before theMRI
examination with gadobutrol;
- History of anaphylactoid or anaphylactic reaction to any contrast
medium;
- Pregnant or lactating women;
- Clinically unstable condition and/or requirement of emergency
treatment and/or physical or mental status, which interfered with
the signing of the informed consent;
- Chronic kidney disease≥3 (glomerular filtration rate<60mL·min−1)
to further reduce the risk of developing nephrogenic systemic fibrosis.TABLE 1. Technical Parameters of the Sequences Used for the MRI of the
Parameters HASTE BLADE
Repetition time, ms 560 5500
Echo time, ms 30 87
Flip angle, degree 150 140
Acquisition matrix 320 384
Field of view, mm 400–500 400–500
GRAPPA 2 2
Spatial resolution, mm3 1.3  1.3  5.0 1.0  1.0  5
Slice orientation Axial Axial
Breath-hold Yes; acquisition
time, 16–19 s
No, respiratory navig
triggering; mean ac
time, 6.3 minutes
Contrast medium Acquisition before
the application of
contrast medium
Acquisition before th
application of cont
medium
HASTE indicates half-Fourier acquisition single-shot turbo spin echo, T2-weighted
parallel lines with enhanced reconstruction, T2-weighted; VIBE, volumetric interpol
with stochastic trajectories, T1-weighted; GRAPPA, generalized autocalibrating parti
734 www.investigativeradiology.com
Copyright © 2015 Wolters Kluwer HThe evaluation included CTand MR imaging as well as clinical,
laboratory, and pulmonary functional examinations, which were all
performed within 5 days to provide a reliable comparison between all
parameters.
CT and MRI Protocols
Chest CTwas performed by a 64-slice multidetector system (GE
Lightspeed VCT 64; General Electric Healthcare, Milwaukee, WI). A
standardized low-dose unenhancedCT protocolwas usedwith the follow-
ing technical parameters in axial slice orientation and inspiratory breath-
hold: tube voltage, 100 kV, dose-modulated tube current, 35–80 mAs;
pitch, 1.375; table speed per rotation, 55.0 mm; reconstruction slice
thickness, 0.625 mm; and effective slice thickness, 5 mm. Lung MRI
was acquired using a 1.5-T system (Magnetom Avanto; Siemens
Healthcare, Erlangen, Germany) with a standardized protocol. The tech-
nical parameters of the used T1- and T2-weighted MRI sequences
are summarized in Table 1; gadobutrol was administered in a dose of
0.1-mmol·kg−1 body weight.
Analysis of Images
All CT and MR images were visually evaluated in consensus by
2 radiologists with experience of at least 5 years in chest imaging. The
observers evaluated all CTand MR images in a blinded manner to clin-
ical and previous radiological data to achieve an appropriate comparison
of imaging. The readers observed the images in a randomized patient order;
to avoid recall bias, the time interval between the analysis of CT and MR
examinationswas at least 3weeks. Two different scoring systemswere used
for all CTandMR images: the morphologic scoring system, developed by
Helbich et al8 and modified by Puderbach et al12 for comparison between
CTandMR examinations in patients with CF (Table 2) as well as the mor-
phologic and functional scoring system developed by Eichinger et al22 for
evaluation of MR images in patients with CF (Table 3).
For analysis of the specific CT and MR imaging pa-
rameters, the following descriptions were used according to
published definitions:
- Bronchiectasis:12,22,28,29 was defined as bronchial dilatation with
respect to the accompanying pulmonary artery, lack of tapering of
bronchi, and identification of bronchi within 1 cm of the pleural sur-
face; in the modified Helbich score, the severity of bronchiectasisLung
VIBE TWIST
3.7 2.4
1.6 0.8
8 25
384 256
400–500 400–500
2 3
.0 1.0  1.0  5.0 2.6  1.6  3.0
Axial Coronal
ator
quisition
Yes; acquisition time per
breath-hold, 16–19 s
No, free-breathing;
25 data sets with
acquisition time of
each, 1.6 s
e
rast
Acquisition of one sequence
before and one sequence
with the same technical
parameters after contrast
medium application
Continuous acquisition
before, during, and
after application of
contrast medium
; BLADE, proprietary name for a sequence using periodically rotated overlapping
ated breath-hold examination, T1-weighted; TWIST, time-resolved angiography
ally parallel acquisition.
© 2015 Wolters Kluwer Health, Inc. All rights reserved.
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TABLE 2. Modified Helbich Scoring System for Evaluation of CT and MR Imaging of the Lung*
Category
Score
0 1 2 3
Severity of bronchiectasis† Absent Mild (bronchial luminal
diameter slightly greater
than the diameter of the
adjacent blood vessel)
Moderate (bronchial lumen
2 to 3 times greater than the
diameter of the adjacent
blood vessel)
Severe (bronchial
lumen >3 times greater
than the diameter of the
adjacent blood vessel)
Severity of peribronchial
wall thickening†
Absent Mild (wall thickness equal
to the diameter of the
adjacent vessel)
Moderate (wall thickness
greater than and up to twice
the diameter of the
adjacent vessel)
Severe (wall thickness
more than twice the
diameter of the
adjacent vessel)
Extent of bronchiectasis‡ Absent 1–5‡ 6–9‡ >9‡
Extent of mucus plugging‡ Absent 1–5‡ 6–9‡ >9‡
Extent of sacculations/
abscesses‡
Absent 1–5‡ 6–9‡ >9‡
Generation of bronchial
divisions involved
(bronchiectasis or
mucus plugging)
Absent Up to the fourth generation Up to the fifth generation Up to the sixth generation
and distal
Severity of bullae Absent Unilateral (numbers not >4) Bilateral (numbers not >4) Numbers >4
Severity of emphysema‡ Absent 1–5‡ >5‡ Not applicable
Severity of collapse/
consolidation
Absent Subsegmental Segmental or lobar Not applicable
*According to the publication of Puderbach et al.12
†The severity of the parameters “bronchiectasis” and “peribronchial wall thickening” was recorded with that score (1–3), whereas most of the imaging features
were present in the lung.
‡These categories are assessed on a segment-based analysis. The numbers represent the involved quantity of bronchopulmonary segments (right lung, 10 segments;
left lung, 8 segments).
TABLE 3. Eichinger Scoring System for Evaluation of CT and MR
Imaging of the Lung*
Parameter
Right lung Left lung Maximal
Parameter/Global
ScoreUL ML LL UL LG LL
1. Bronchiectasis/
(peri-)bronchial wall
thickening†
12
2. Mucus plugging† 12
3. Sacculations/
abscesses†
12
4. Consolidation† 12
5. Special findings† 12
6. Perfusion size†‡ 12
Maximal lobar/
global score
12 12 12 12 12 12 72
*According to the publication of Eichinger et al.22
†Each parameter is assessed on a lobe-based analysis by rating with 3 scores:
0, pathology not present in this lobe; 1, <50% of the lobe involved; 2, ≥50% of
the lobe involved.
‡The "perfusion size" is solely evaluated for the MR, not for the CT images.
UL indicates upper lobe; ML, middle lobe; LL, lower lobe; LG, lingula.
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©was estimated by comparing the bronchial luminal diameter with the
size of the adjacent artery;
- Peribronchial wall thickening 12,22 was separately assessed in the
modified Helbich score in comparison with the adjacent artery;
bronchiectasis and bronchial wall thickening were recorded as
one single parameter in the Eichinger score;
- Mucus plugging12,21,22,28 was defined as fluid content within dilated
bronchi greater than 3 mmwithout signal enhancement after contrast
medium administration; peripheral mucus plugging can demonstrate
a grapelike or “tree-in-bud” appearance. If mucus plugging was ob-
served in the periphery, this segment or lobe was also scored for the
parameter bronchiectasis;
- Sacculation/abscess12,22,29 was regarded as a circular structure with
a diameter greater than 1.5 cm, which was air-filled or showed an
air-fluid level and had a thick wall;
- Collapse/consolidation12,22,28,29 was defined as a homogeneous in-
crease in pulmonary parenchymal density (CT) or signal intensity
(MRI) with a size greater than 2 cm, which obscured the margins
of vessels and airway walls; it can be caused by alveolar filling with
inflammatory fluid and/or by atelectasis;
- Bulla12,28 was regarded as a sharply demarcated airspace with a di-
ameter greater than 1 cm and a thin wall (<1 mm thickness) in the
modified Helbich score (Table 2). In the Eichinger score, this pa-
rameter was not considered;
- Emphysema12,28 was defined as an area of decreased density (CT)
or signal intensity (MRI) compared with the surrounding lung paren-
chyma combinedwith a reduction of vessels. In themodifiedHelbich
score, this parameter was documented on a segmental basis (Table 2).
This imaging feature was not considered in the Eichinger score;
- Special findings22: In the Eichinger score, pleural affection, eg, ef-
fusion or pneumothorax, was recorded as special finding (Table 3).
This parameter was not documented in the modified Helbich score;2015 Wolters Kluwer Health, Inc. All rights reserved.
Copyright © 2015 Wolters Kluwer He- Perfusion size22: Eichinger et al22 described the size of a perfusion
defect as the functional parameter perfusion size; the lung perfusion
was assessed on the time point of maximum pulmonary enhance-
ment on subtraction images of the time-resolved angiography with
stochastic trajectories (TWIST) sequences (Tables 1 and 3). Thiswww.investigativeradiology.com 735
alth, Inc. All rights reserved.
Renz et al Investigative Radiology • Volume 50, Number 10, October 2015parameter was not determined in the evaluation of CT images and
the analysis based on the modified Helbich score.
The modified Helbich score provided a maximum of 25 points
(Table 2). The Eichinger score consisted of 2 subscores: morphologic
score (parameters 1–5, Table 3) with a maximum of 60 points (valid
for CT and MRI) and functional score (lung perfusion only assessed
on MRI, maximum of 12 points). In addition to the modified Helbich
and Eichinger scores, the following MRI characteristics were analyzed:
signal intensity of most of the peribronchial walls and visible mucus
on T2-weighted images as well as the signal enhancement of most
of peribronchial walls on contrast-enhanced volumetric interpolated
breath-hold examination (VIBE) sequences (Table 1). For these evalu-
ations, an ordinal 3-point scale was used:
- 0 = normal signal intensity and normal signal enhancement of the
peribronchial walls/no mucus detected;
- 1 = moderately high signal intensity of the peribronchial walls
and the mucus/moderately increased signal enhancement of the
peribronchial walls;
- 2 = severely high signal intensity of the peribronchial walls and the
mucus/severely increased signal enhancement of the peribronchial walls.
Furthermore, the readers assessed the subjective overall image
quality of the CTandMR examinations on a 5-point Likert scale, where
the reference was an “ideal exam”:30
- 1 = nondiagnostic image quality;
- 2 = poor image quality, many artifacts;
- 3 = sufficient image quality for diagnostic purposes, some artifacts;
- 4 = good image quality, few artifacts;
- 5 = excellent image quality, no artifacts.
Clinical and Functional Characteristics
The clinical status of the patients was determined by using the
pulmonary exacerbation assessed by the modified criteria of Fuchs
et al.31,32 According to these modified Fuchs criteria,31 pulmonary ex-
acerbation was defined as the need for additional antibiotic treatment
due to a recent change in at least 2 of the following 6 symptoms:
- Change in sputum volume and/or sputum color;
- Increased cough;
- Increased malaise, fatigue, or lethargy;
- Anorexia or significant weight loss;
- Decrease in pulmonary function by 10%;
- Increased dyspnea.
For this study, the modified Fuchs criteria were used as a score
ranging from 0 to 6 (based on the present clinical categories). As further
clinical parameter, the presence of chronic pulmonary colonization by
Pseudomonas aeruginosa of the patients was assessed. Serum levels
of C-reactive protein in mg·L−1 and immunoglobulin G (IgG) in
mg·dL−1, as well as the number of leucocytes per nanoliter (nL) were
recorded as blood laboratory values for inflammatory activity of CF.
Body plethysmography was performed as a pulmonary functional test
and included the following parameters: forced vital capacity, forced ex-
piratory volume in the first second, residual volume, effective resis-
tance, and the maximum midexpiratory flow 25% to 75%. The
pulmonary functional results were expressed as percentages of refer-
ence values of healthy individuals.
Statistical Evaluation
Statistical analysis was performed using SPSS version 20.0 for
Windows (IBM SPSS Statistics, Chicago, IL) and MedCalc version
14.0 for Windows (MedCalc Software; Mariakerke, Belgium). First,
the prevalence of all clinical, pulmonary functional, and imaging pa-
rameters was determined. Differences between CTandMR examinations
were assessed by Wilcoxon rank sum tests and Student t tests. Con-
cordance correlation coefficients (CCCs) were used to determine the736 www.investigativeradiology.com
Copyright © 2015 Wolters Kluwer Hagreement between CTandMR examinations for all imaging parameters.
Spearman rank correlation coefficients were calculated to analyze the as-
sociation of imaging findings to clinical findings including pulmonary
functional results. Bland-Altman plotswere performed for the overall mod-
ified Helbich and the Eichinger score to assess the overall agreement be-
tween CT and MRI; the mean of the score differences including the
upper and the lower limits of agreement were determined. In all statistical
tests, P < 0.05 (2-sided) was considered to indicate significant differences.
RESULTS
Patients' Characteristics
Thirty-two patients with CF were enrolled in the study. Two pa-
tients had to be excluded of whom one patient refused the MR exami-
nation after initial written consent at the date of MR examination; the
MR examination was interrupted in one patient owing to dyspnea during
scanning. Thus, 30 patients [17men and 13women; mean (SD) age, 30.2
(9.2); range, 19–52 years] were included; their mean (SD) body mass in-
dex was 20.9 (3.6) kg·m−2; range, 14.6–32.1 kg·m−2. In the 30 patients,
the following pulmonary exacerbation scores based on the modified
Fuchs criteria were determined [mean (SD), 3.1 (2.1); median, 3.5;
IQR, 4.0]: score 0, n = 5; 1, n = 5; 2, n = 2; 3, n = 3; 4, n = 4; 5,
n = 8; and 6, n = 3. Twenty (66.7%) of 30 patients had chronic pulmo-
nary colonization by P. aeruginosa. The mean (SD) blood laboratory pa-
rameters of the 30 patients were as follows: C-reactive protein, 36.9
(54.4) mg·L−1 (range, 0.5–208.2 mg·L−1); IgG, 1681.1 (444.4) mg·dL−1
(range, 941.0–2433.0 mg·dL−1), and number of leucocytes, 13.4 (4.9) per
nL (range, 4.0–22.5 per nL). The pulmonary functional tests resulted in
the following mean (SD) values: forced vital capacity, 71.6% (23.2%)
(range, 28.4%–116.0%); forced expiratory volume in the first second,
53.6% (22.9%) (range, 21.0%–94.6%); residual volume, 164.9% (56.7%)
(range, 38.3%–271.8%); effective resistance, 214.2% (118.6%) (range,
57.1%–469.7%); and maximum midexpiratory flow 25% to 75%, 27.6%
(22.5%) (range, 8.9%–104.5%).
Imaging Findings
Results of the imaging analysis by the modified Helbich score
are summarized in Table 4 for the CT in comparison to the MR exam-
inations. The differences of the scores between CT and MR examina-
tions were not significant for all imaging features (Wilcoxon rank
sum tests; P > 0.05). The overall modified Helbich CT score had amean
(SD) of 15.3 (4.8) (range, 3–21) and amedian of 16.0 (IQR, 6.3). The over-
all modified Helbich MR score showed slightly, not significantly, lower
values (Wilcoxon rank sum test and Student t test; P > 0.05): a mean
(SD) of 14.3 (4.7) (range, 3–20) and a median of 15.0 (IQR, 7.3).
In accordance with the results of the modified Helbich score,
all 30 patients showed bronchiectasis/peribronchial wall thickening on
CT and MR examinations, assessed by the Eichinger score (Fig. 1).
The mean and median scores of this imaging feature were as follows
for CT versus MR examinations: mean (SD), 9.3 (2.4) (range, 4–12);
median, 10.0 (IQR, 3.3) versus mean (SD), 9.0 (2.3) (range, 4–12); me-
dian, 9.0 (IQR, 3.0). Twenty-eight of the 30 patients had mucus plug-
ging on CT and MR examinations with the following mean and
median Eichinger scores: mean (SD), 7.9 (3.2) (range, 0–12); and me-
dian, 8.0 (IQR, 4.0) on CT; and mean (SD), 7.2 (3.3) (range, 0–12);
and median, 7.5 (IQR, 5.0) on MRI (Fig. 2). In accordance with the
modified Helbich score, one third of the patients (10/30 patients;
33.3%) showed sacculations/abscesses on CT versus MRI with the fol-
lowing Eichinger scores: 1, n = 5; 2, n = 2; 4, n = 1; 6, n = 2 versus 1,
n = 5; 2, n = 3; 5, n = 1; 6, n = 1. Consolidation was observed in 19
(63.3%) of the 30 patients on CT: score 1, n = 5; 2, n = 6; 3, n = 6; 4,
n = 1; 6, n = 1. On MRI, consolidation was found in 18 (60.0%) of
the 30 patients: score 1, n = 4; 2, n = 6; 3, n = 5; 4, n = 2; 6, n = 1. Spe-
cial findings, that means pleural affection, were detected in 9 (30.0%) of
the 30 patients with the following Eichinger scores on CT: score 1,© 2015 Wolters Kluwer Health, Inc. All rights reserved.
ealth, Inc. All rights reserved.
TABLE 4. Imaging Findings in 30 Patients With CF Assessed by the Modified Helbich Scoring System Based on CT and MR Examinations
Category
Score Based on CT Examinations Score Based on MR Examinations
0 1 2 3 0 1 2 3
Severity of bronchiectasis 0 (0.0) 5 (16.7) 11 (36.7) 14 (46.7) 0 (0.0) 6 (20.0) 10 (33.3) 14 (46.7)
Severity of peribronchial wall thickening 3 (10.0) 9 (30.0) 10 (33.3) 8 (26.7) 5 (16.7) 7 (23.3) 13 (43.3) 5 (16.7)
Extent of bronchiectasis 0 (0.0) 2 (6.7) 3 (10.0) 25 (83.3) 0 (0.0) 2 (6.7) 4 (13.3) 24 (80.0)
Extent of mucus plugging 2 (6.7) 2 (6.7) 6 (20.0) 20 (66.7) 2 (6.7) 3 (10.0) 8 (26.7) 17 (56.7)
Extent of sacculations/abscesses 20 (66.7) 7 (23.3) 1 (3.3) 2 (6.7) 20 (66.7) 8 (26.7) 1 (3.3) 1 (3.3)
Generation of bronchial divisions involved
(bronchiectasis or mucus plugging)
0 (0.0) 2 (6.7) 9 (30.0) 19 (63.3) 0 (0.0) 5 (16.7) 12 (40.0) 13 (43.3)
Severity of bullae 14 (46.7) 5 (16.7) 4 (13.3) 7 (23.3) 15 (50.0) 5 (16.7) 4 (13.3) 6 (20.0)
Severity of emphysema 12 (40.0) 8 (26.7) 10 (33.3) — 16 (53.3) 6 (20.0) 8 (26.7) —
Severity of collapse/consolidation 11 (36.7) 11 (36.7) 8 (26.7) — 12 (40.0) 10 (33.3) 8 (26.7) —
The data are presented as number of patients and percentages (in parentheses). The percentages may not add up to 100.0% owing to rounding off.
Investigative Radiology • Volume 50, Number 10, October 2015 Comparison Between Lung MRI and CT in CF Patientsn = 1; 2, n = 3; 3, n = 3; 4, n = 2. On MRI, this imaging feature was ob-
served in 12 (40.0%) of the 30 patients: score 1, n = 3; 2, n = 4; 3, n = 2;
4, n = 2; 5, n = 1 (Fig. 2). Perfusion deficits were detected in 24 (80.0%)FIGURE 1. Computed tomography (A) and MR (B) examination of a
30-year-oldmale patientwith CF. The unenhanced, low-dose, transversal
CT image (A) shows bronchiectasis in the left and right upper lobe with
peribronchial wall thickening, which is also visualized in the T1-weighted
VIBE sequence (B), acquired after intravenous contrast medium
administration (continuous lines). The VIBE sequence distinctly shows the
characteristic signet ring sign of the bronchiectasis owing to the bright
contrast enhancement of the accompanying bronchial arteries
(continuous arrows). In the central lung area, small bronchiectasis with
peribronchial wall thickening, clearly detected onCT, can be also seen on
MRI (discontinuous lines). In the lung periphery, small bronchiectasis can be
visualized only on the CT, not on the MR image (discontinuous arrows).
© 2015 Wolters Kluwer Health, Inc. All rights reserved.
Copyright © 2015 Wolters Kluwer Hof the 30 patients on MRI, with a mean (SD) score of 4.0 (3.2) and a
median score of 3.5 (IQR, 6.3). Without assessment of perfusion, the
overall Eichinger score resulted in the following values for CT versus
MR examinations: mean (SD), 20.3 (7.2) (range, 4–31); and median,FIGURE 2. Computed tomography (A) and MR (B) examination of a
20-year-old female patient with CF. The unenhanced, low-dose,
transversal CT image (A) demonstrates ubiquitary bronchiectasis with
peribronchial wall thickening, which is also visualized in the
T2-weighted BLADE sequence (B; continuous lines). Mucus plugging,
detected clearly onCT, can be distinctly seen onMRI as well, even in the
peripheral lung areas (continuous arrows). However, small bronchiectasis
can be visualized only on the CT image, not on the MR image in the
lung periphery (discontinuous arrows). The CT and the MR examinations
show pleural affection in the right lung segment 6 (discontinuous lines).
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TABLE 5. Additional Imaging Characteristics in 30 Patients With CF
Determined by MR Examinations
Category 0 1 2
Contrast medium-induced signal
enhancement of the peribronchial walls
8 (26.7) 11 (36.7) 11 (36.7)
T2-weighted signal intensity of the
peribronchial walls
9 (30.0) 15 (50.0) 6 (20.0)
T2-weighted signal intensity
of detected mucus
2 (6.7) 13 (43.3) 15 (50.0)
The data are presented as number of patients and percentages (in parentheses).
The percentages may not add up to 100.0% owing to rounding off.
Renz et al Investigative Radiology • Volume 50, Number 10, October 201521.0 (IQR, 9.5) versus mean (SD), 19.5 (7.1) (range, 4–33); and me-
dian, 20.0 (IQR, 9.0). All differences between CT and MR examina-
tions were not significant (Wilcoxon rank sum tests and Student t
tests; P > 0.05).
The prevalences of the additional MRI characteristic signal
intensity/signal enhancement of peribronchial walls and signal intensity
of detected mucus are presented in Table 5. The overall image quality
was higher for the CT examinations compared to the MRI sequences:
mean (SD), 4.1 (0.8) (range, 3–5); median, 4.0 (IQR, 1.3) versus mean
(SD), 3.5 (0.8) (range, 2–5); median, 3.5 (IQR, 1.0); the difference of
image quality reached statistical significance (Wilcoxon rank sum test
and Student t test; P < 0.05).TABLE 6. Spearman Correlation Coefficients Between CT and MR Imagin
Findings, and Pulmonary Functional Test Results in 30 Patients With CF
Parameters
Score of Modified
Fuchs criteria CRP
CT: Severity of bronchiectasis 0.75† 0.42*
MRI: Severity of bronchiectasis 0.67† 0.43*
CT: Severity of peribronchial wall thickening 0.50† 0.43*
MRI: Severity of peribronchial wall thickening 0.46* 0.41*
CT: Extent of bronchiectasis 0.51† 0.37*
MRI: Extent of bronchiectasis 0.46* 0.33*
CT: Extent of mucus plugging 0.58† 0.61†
MRI: Extent of mucus plugging 0.54† 0.62†
CT: Extent of sacculations/abscesses 0.45* 0.27
MRI: Extent of sacculations/abscesses 0.44* 0.29
CT: Generation of bronchial divisions involved 0.47* 0.43*
MRI: Generation of bronchial divisions involved 0.36* 0.41*
CT: Severity of bullae 0.27 0.28
MRI: Severity of bullae 0.25 0.26
CT: Severity of emphysema 0.26 0.16
MRI: Severity of emphysema 0.18 0.09
CT: Severity of collapse/consolidation 0.24 0.21
MRI: Severity of collapse/consolidation 0.21 0.22
Overall modified Helbich CT score 0.67† 0.62†
Overall modified Helbich MRI score 0.58† 0.57†
Overall modified Helbich MRI score
plus additional 3 MRI parameters
0.69† 0.63†
*P < 0.05.
†P < 0.01.
CRP indicates C-reactive protein; IgG, immunoglobulin G; FVC, forced vital cap
R, effective resistance; MMEF 75/25, maximum midexpiratory flow 25%–75%.
738 www.investigativeradiology.com
Copyright © 2015 Wolters Kluwer HAssociations Between Imaging and Clinical Findings
Using the modified Helbich score, the CCCs between the differ-
ent CTand MR imaging parameters ranged from 0.57 (category gener-
ation of bronchial divisions involved) to 0.97 (parameter severity of
collapse/consolidation); the CCC was 0.94 for the overall scoring
system. For the Eichinger score, the CCCs between the different CT
and MR imaging parameters ranged from 0.84 (category special
findings) to 0.98 (parameter consolidation). The overall Eichinger score
(without perfusion measurement) showed a CCC of 0.95 between CT
and MR examinations.
The CT and MRI values from both scoring systems showed
no difference in patients with chronic pulmonary colonization by P.
aeruginosa compared to those without chronic pulmonary colonization
(Wilcoxon rank sum tests and Student t tests; P > 0.05). Correlation co-
efficients between imaging findings in comparison with the pulmonary
exacerbation rate score (modified Fuchs criteria), blood laboratory
results, and pulmonary functional test are summarized in Tables 6
and 7. In general, these correlations were higher for both overall scoring
systems compared with the specific imaging parameters. The correla-
tions of the CT scores to the clinical, laboratory, and pulmonary func-
tional parameters were slightly higher compared with the MRI scores
(Tables 6 and 7). However, if the additional MRI parameters were inte-
grated into the scoring systems, the correlations reached the values of
the CT scores (Tables 6 and 7). The results of the Bland-Altman plots
are shown in Figure 3 (for the overall modified Helbich score) and
Figure 4 (for the overall Eichinger score); the Bland-Altman plots re-
vealed a strong agreement betweenMR and CT imaging for both scoresg Results (Using the Modified Helbich Scoring System), Clinical
IgG No. of leucocytes FVC FEV1 RV R MMEF 75/25
0.19 0.42* −0.60† −0.62† 0.57† 0.44* −0.59†
0.37* 0.39* −0.54† −0.59† 0.51† 0.46* −0.57†
0.28 0.52† −0.45* −0.47* 0.37* 0.38* −0.49*
0.18 0.53† −0.41* −0.47* 0.30 0.38* −0.47*
0.12 0.44* −0.31* −0.43* 0.62† 0.45* −0.51†
0.09 0.40* −0.29 −0.42* 0.59† 0.42* −0.49*
0.21 0.49* −0.38* −0.49* 0.47* 0.45* −0.49*
0.23 0.43* −0.36* −0.48* 0.43* 0.43* −0.48*
0.19 0.27 −0.42* −0.47* 0.44* 0.43* −0.53†
0.17 0.27 −0.40* −0.45* 0.43* 0.41* −0.51†
0.44* 0.51† −0.35* −0.50† 0.53† 0.46* −0.51†
0.28 0.42* −0.29 −0.35* 0.39* 0.31* −0.37*
0.06 0.14 −0.18 −0.27 0.41* 0.24 −0.20
0.07 0.21 −0.19 −0.26 0.35* 0.24 −0.18
0.10 0.39* −0.26 −0.34* 0.38* 0.36* −0.45*
0.06 0.34* −0.23 −0.31* 0.36* 0.27 −0.41*
0.22 0.38* −0.36* −0.30* 0.22 0.22 −0.27
0.18 0.32* −0.33* −0.27 0.18 0.18 −0.26
0.32* 0.63† −0.53† −0.63† 0.66† 0.54† −0.65†
0.26 0.59† −0.51† −0.59† 0.58† 0.51† −0.62†
0.28 0.66† −0.54† −0.61† 0.63† 0.53† −0.64†
acity; FEV1, forced expiratory volume in the first second; RV, residual volume;
© 2015 Wolters Kluwer Health, Inc. All rights reserved.
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TABLE 7. Spearman Correlation Coefficients Between CT and MR Imaging Results (Using the Eichinger Scoring System), Clinical Findings, and
Pulmonary Functional Test Results in 30 Patients with CF
Parameters
Score of Modified
Fuchs Criteria CRP IgG No. of leucocytes FVC FEV1 RV R MMEF 75/25
CT: Bronchiectasis/peribronchial wall thickening 0.58† 0.68† 0.42* 0.47* −0.46* −0.58† 0.60† 0.49* −0.65†
MRI: Bronchiectasis/peribronchial wall thickening 0.59† 0.64† 0.33* 0.48* −0.42* −0.55† 0.57† 0.48* −0.60†
CT: Mucus plugging 0.66† 0.61† 0.40* 0.58† −0.64† −0.68† 0.61† 0.58† −0.70†
MRI: Mucus plugging 0.60† 0.55† 0.31* 0.55† −0.58† −0.64† 0.45* 0.56† −0.61†
CT: Sacculations/abscesses 0.46* 0.24 0.18 0.28 −0.43* −0.47* 0.47* 0.42* −0.53†
MRI: Sacculations/abscesses 0.44* 0.25 0.18 0.28 −0.41* −0.46* 0.46* 0.41* −0.52†
CT: Consolidation 0.24 0.19 0.37* 0.35* −0.37* −0.30* 0.17 0.21 −0.26
MRI: Consolidation 0.22 0.18 0.38* 0.33* −0.35* −0.29 0.12 0.19 −0.23
CT: Special findings 0.23 0.29 0.24 0.33* −0.42* −0.45* 0.29 0.40* −0.44*
MRI: Special findings 0.18 0.25 0.17 0.27 −0.41* −0.40* 0.24 0.35* −0.40*
Overall Eichinger CT score without perfusion 0.68† 0.63† 0.41* 0.62† −0.71† −0.72† 0.64† 0.64† −0.73†
Overall Eichinger MRI score without perfusion 0.65† 0.55† 0.39* 0.60† −0.64† −0.67† 0.57† 0.62† −0.70†
MRI: Perfusion size 0.61† 0.62† 0.40* 0.57† −0.58† −0.65† 0.51† 0.53† −0.64†
Overall Eichinger MRI score with perfusion 0.67† 0.69† 0.44* 0.61† −0.66† −0.71† 0.58† 0.63† −0.73†
Overall Eichinger MRI score with perfusion
plus additional 3 MRI parameters
0.71† 0.70† 0.47* 0.66† −0.67† −0.71† 0.60† 0.65† −0.74†
*P < 0.05.
†P < 0.01.
CRP indicates C-reactive protein; IgG, immunoglobulin G; FVC, forced vital capacity; FEV1, forced expiratory volume in the first second; RV, residual volume;
R, effective resistance; MMEF 75/25, maximum midexpiratory flow 25%–75%.
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all Eichinger score, 0.8).
DISCUSSION
Supported by continuously improved technical developments,
MRI has increasingly been discussed as an adequate radiation-free alter-
native to CT for some lung disorders. In this study, we could verify thatFIGURE 3. The Bland-Altman plot shows the difference of the overall modified
(the image only shows 23 points because of the overlap of 7 values). With a p
examinations will be in-between the upper limit of agreement (+3.9) and the
at www.investigativeradiology.com.
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Copyright © 2015 Wolters Kluwer Hif all information from the MR images is considered, MRI can de-
monstrate similar correlation to laboratory and pulmonary functional pa-
rameters as well as to the grade of pulmonary exacerbation at the time of
lung imaging. Additionally, the concordance between CTandMR exam-
inations was very high, with coefficients of 0.94 (overall modified
Helbich score) and 0.95 (overall Eichinger score without perfusion mea-
surement). Puderbach et al12 also performed a comparison study of CTHelbich score between the CT andMR examinations in 30 patients with CF
robability of 95%, the differences between further CT and MR
lower limit of agreement (−1.8). Figure 3 can be viewed online in color
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FIGURE 4. The Bland-Altman plot shows the difference of the overall Eichinger score between the CT and MR examinations in 30 patients with CF
(the image only shows 27 points because of the overlap of 3 values). With a probability of 95%, the differences between further CT andMR examinations
will be in-between the upper limit of agreement (+4.0) and the lower limit of agreement (−2.4). Figure 4 can be viewed online in color at
www.investigativeradiology.com.
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out, however, considering any clinical or additional MRI parameters. The
authors found an overall correlation of 0.80 between CT and MR im-
ages.12 Montella et al33 investigated whether 3-T MRI was as effective
as CT in identifying pulmonary abnormalities in primary ciliary dyskine-
sia also using the modified Helbich score; the overall correlation of 0.95
in this study was similar to our findings. One possible explanation for the
inferior correlation in the study of Puderbach et al12 could be that the pa-
tients were younger (mean age, 16.7 years), resulting in a lower median
overall score of 13.0 (MRI) and 13.5 (CT).
Despite technical developments, subtle pulmonary changes and
peripheral bronchi (resulting in a relatively low correlation of the cate-
gory generation of bronchial divisions involved between MRI and CT)
can be still less clearly visualized onMRI owing to its lower spatial res-
olution.12,21 Therefore, the CT examinations reached in general higher
values in all morphologic parameters of both scoring systems in our
study. Owing to breathing artifacts in breath-hold MRI sequences, the
impaired spatial resolution, and the relatively low and heterogeneous
pulmonary signal-to-noise ratio, the diagnostic image quality of lung
MRI is challenging.12,21,34 In this consequence, the overall diagnostic
image quality was significantly inferior for MR compared with CTex-
aminations in our investigation. However, all MR examinations were of
diagnostic quality with a mean value of 3.5 (between sufficient and
good image quality); in 3 patients with CF, the MR examination was
rated as score 2 (poor image quality with many artifacts). All 3 patients
had severe CF lung manifestation with decreased pulmonary functional
capacity and therefore CF-related limitations in sufficient breath-hold,
leading to poor image quality in particularly the half-Fourier acquisi-
tion single-shot turbo spin echo (HASTE) and volumetric interpolated
breath-hold examination (VIBE) sequences. Thus, sequences acquired
with respiratory navigating should be part of a routine protocol of lung
MRI, especially in patients with impaired clinical status.
It has been not evaluated in detail so far, whether the clear visu-
alization of subtle pulmonary pathologies are important for the severity
assessment and the prognosis of CF lung disease. Thus, we correlated
CT and MR imaging findings to the clinical status of the patients740 www.investigativeradiology.com
Copyright © 2015 Wolters Kluwer Hincluding their pulmonary exacerbation grade. Helbich et al8 compared
CT imaging (assessed by the Helbich score) with pulmonary functional
test results, serum IgG values, and a clinical scoring system in patients
with CF. The Spearman correlation coefficients between the different
morphologic CT parameters and the IgG levels ranged from 0.29 to
0.69 in the study of Helbich et al,8 indicating higher values than
our correlations with IgG levels (CT, 0.06–0.44). Hypergamma-
globulinemia has been proven to predict pulmonary progression in
CF35; however, only few patients with CF demonstrate manifest
hypergammaglobulinemia, minimizing its importance for the deter-
mination of CF disease severity.35,36
The Spearman correlation coefficients between CT imaging and
pulmonary functional parameters, published by Helbich et al,8 were
similar to our calculated coefficients. Accordingly, some imaging fea-
tures showed higher correlations to pulmonary functional parameters,
such as severity/extent of bronchiectasis or extent of mucus plugging,
than others, such as severity of bullae/emphysema; whereas these differ-
ences were similar for CTand MRI. Computed tomography scores have
been described to can be even more sensitive than pulmonary functional
parameters in the detection of early CF lung disease and in determining
the progression of lung manifestation.10,29,37,38 Oikonomou et al10 re-
ported that simplification of the CT scoring systems provided even better
findings than the original more extent scores. The more simplified structure
of the Eichinger scoring systemmight be onemain reason that the Eichinger
score showed in general higher clinical correlations and stronger agreement
between CTand MRI demonstrated in the Bland-Altman plot (Fig. 4) than
the modified Helbich scoring system. Furthermore, the Eichinger score was
specifically developed for the assessment of lung MRI in CF. Wielpütz
et al14 also used the Eichinger scoring system for the assessment of lung
MRI in children with early CF lung disease; in patients with pulmonary
exacerbations, the overall mean scorewas 18.0 (SD 2.0) and was signif-
icantly reduced to 12.0 (SD 3.0) after antibiotic treatment.14
Some imaging features have been omitted in the Eichinger scor-
ing system, such as the separate analysis of severity of bronchiectasis
and severity of peribronchial wall thickening. The parameter bron-
chiectasis has been proven as an outcome predictor for the number of© 2015 Wolters Kluwer Health, Inc. All rights reserved.
ealth, Inc. All rights reserved.
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wall thickening might represent more distinctly the inflammatory activ-
ity of the peribronchial walls at the time of pulmonary exacerbation;
high T2-weighted signal (ie, edema) and strong contrast medium en-
hancement of the peribronchial walls might reflect the inflammatory ac-
tivity even more specifically.13,21,29 As far as we know, the structured,
detailed MRI evaluation of the peribronchial walls and of visible mucus
was performed in this study for the first time in CF.
Another parameter, which could be solely assessed on MRI, is
the functional parameter of lung perfusion. On CT, this parameter
can be determined only if a relatively high additional x-ray exposure
is used. Despite the upcoming possibility of potent iterative reconstruc-
tion techniques to reduce radiation exposure, the cumulative radiation
exposure of CTexaminations can still become complicated for patients
with CF, particularly if additional series, such as lung perfusion, are
acquired.8–11,31,39 Pulmonary perfusion CT can be assessed using dual-
energy techniquewith less but also additional radiation dose.40 The cor-
relation of MR perfusion imaging to clinical and especially pulmonary
functional parameters was high in our study, as both assessments are of
functional origin. According toWielpütz et al,14 regional perfusion def-
icits are early signs of pulmonary manifestations in CF and can be even
detected in infants and preschool children in stable clinical condition.
Lung perfusion imaging has a relatively low acquisition time of up to
2 minutes and should therefore be part of a routine MRI protocol in
CF. When all additional MRI parameters were considered, the correla-
tions between MR imaging and clinical, laboratory, and pulmonary
functional parameters were similar to the correlation coefficients of
CTexaminations, although the overall image quality ofMRI was signif-
icantly inferior. Thus, the imaging of subtle pulmonary pathologies by
CT seems to be of minor clinical importance.
The following limitations of this study should be noted. All im-
ages were evaluated in consensus, and therefore inter-reader variability
was not calculated; Eichinger et al22 reported a high inter-reader agree-
ment (CCC 0.97) of the overall MR Eichinger score. As the inclusion
criteria necessitated a homogeneous study design, such as data acquisi-
tion within 5 days, only a limited number of 30 patients could be in-
cluded. The time interval of maximum 5 days between the 2 imaging
examinations and the acquisition of clinical, laboratory, and pulmonary
functional parameters might lead to some disproportionate correlations.
However, in the trial of Puderbach et al,12 the time interval between CT
and MRI was at maximum 4 weeks; this higher interval might be one
reason that the agreement between the 2 imaging modalities was lower
than in our study: mean of the difference in the Bland-Altman plot of
the modified Helbich score, 2.7 versus 1.1 (Fig. 3). Another reason
for the higher agreement in our study might be that the median overall
modified Helbich score of CTand MRI was higher in our investigation
compared to the values reported by Puderbach et al.12 Thus, the older
patients of our study demonstrated more severe imaging pathologies,
which might provide better correlations of MR to CT examinations as
well as clinical, laboratory, and functional parameters. Helbich et al8
found a significantly higher onset of all CT parameters with increasing
age of the patients with CF. A distinct evaluation of the MRI scoring
systems in the case of early pulmonary CF changes especially in chil-
dren, including a detailed comparison to their clinical status, would fur-
ther advance the implementation of lung MRI in patients with CF in a
clinical setting.
CONCLUSIONS
The findings of this prospective investigation indicate that MRI
of the lung provide similar correlations to clinical, laboratory, and pul-
monary functional parameters compared with chest CT, even if the
overall image quality of MRI is inferior. Thus, lung MRI can also be
used as a reliable surrogate marker for the severity of pulmonary man-
ifestation in patients with CF, as an alternative to chest CT. A principal
advantage of MRI is the possibility to determine multiple morphologic© 2015 Wolters Kluwer Health, Inc. All rights reserved.
Copyright © 2015 Wolters Kluwer Hand functional pulmonary imaging features without the use of any radi-
ation exposure, particularly with regard to the continuously increasing
life expectancy of patients with CF.
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